Experimental and Molecular Medicine

Korean Society for Biochemistry and Molecular Biongy (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells $via$ death receptor 5 upregulation

  • Moon, Myung-Hee (Center for Healthcare Technology Development, Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National University) ;
  • Jeong, Jae-Kyo (Center for Healthcare Technology Development, Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National University) ;
  • Seo, Jae-Suk (Center for Healthcare Technology Development, Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National University) ;
  • Seol, Jae-Won (Center for Healthcare Technology Development, Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National University) ;
  • Lee, You-Jin (Center for Healthcare Technology Development, Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National University) ;
  • Xue, Meilang (Sutton Arthritis Research Laboratories, Institute of Bone and Joint Research, Kolling Institute, University of Sydney at Royal North Shore Hospital St. Leonards) ;
  • Jackson, Christopher J. (Sutton Arthritis Research Laboratories, Institute of Bone and Joint Research, Kolling Institute, University of Sydney at Royal North Shore Hospital St. Leonards) ;
  • Park, Sang-Youel (Center for Healthcare Technology Development, Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National University)
  • Accepted : 2011.01.03
  • Published : 2011.03.31
⟨ Previous Next ⟩

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily of cytokines, is one of the most promising candidates for cancer therapeutics. However, many osteosarcomas are resistant to TRAIL. Bisphosphonates are very effective in the treatment of bone problems associated with malignancies; the antitumor effects are due to the inhibition of protein prenylation that is essential for cell function and survival. The purpose of this study was to determine the effects of bisphosphonates on TRAIL-resistant MG 63 human osteosarcoma cells. The cells showed no response to TRAIL alone; however, pre-treatment with bisphosphonates significantly increased TRAIL-mediated apoptosis and cellular activation of caspase-3. Bisphosphonates significantly induced mRNA and protein expression of the TRAIL receptor, DR5. Bisphosphonates induced protein unprenylation in MG 63 cells; in addition, co-treatment with TRAIL also significantly increased protein unprenylation. Blocking of protein unprenylation using geranylgeraniol attenuated the cellular responses, including cell apoptosis and protein unprenylation induced by bisphosphonates and TRAIL. This is the first study to demonstrate that bisphosphonates markedly enhanced TRAIL-induced apoptosis in human osteosarcoma cells. These findings suggest that bisphosphonates may be a new and effective anticancer treatment with TRAIL proteins for TRAIL-resistant cancer cells.

Keywords

Acknowledgement

Supported by : National Research Foundation of the Korea

References

  1. Brining SK. Predicting the in vitro toxicity of synthetic betaamyloid (1-40). Neurobiol Aging 1997;18:581-589 https://doi.org/10.1016/S0197-4580(97)00153-X
  2. Cabral LA, Werkman C, Brandao AA, Almeida JD. Imprint cytology of osteosarcoma of the jaw: a case report. J Med Case Reports 2009;3:9327 https://doi.org/10.1186/1752-1947-3-9327
  3. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006;6:1075-1085 https://doi.org/10.1586/14737140.6.7.1075
  4. Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971-4974 https://doi.org/10.1158/0008-5472.CAN-05-0264
  5. Coleman RE. Bisphosphonates in breast cancer. Ann Oncol 2005;16:687-695 https://doi.org/10.1093/annonc/mdi162
  6. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000;15:1467-1476 https://doi.org/10.1359/jbmr.2000.15.8.1467
  7. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004;94:164-170 https://doi.org/10.1111/j.1464-4096.2004.04831.x
  8. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284 https://doi.org/10.1038/nrc1590
  9. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, Findlay DM. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002;99: 491-504 https://doi.org/10.1002/ijc.10376
  10. Hori T, Kondo T, Kanamori M, Tabuchi Y, Ogawa R, Zhao QL, Ahmed K, Yasuda T, Seki S, Suzuki K, Kimura T. Ionizing radiation enhances tumor necrosis factor-related apoptosisinducing ligand (TRAIL)-induced apoptosis through upregulations of death receptor 4 (DR4) and death receptor 5 (DR5) in human osteosarcoma cells. J Orthop Res 2010;28: 739-745
  11. Kavanagh K, Guo K, Dunford J, Wu X, Knapp S, Ebetino F, Rogers M, Russell R, Oppermann U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006;103:7829 https://doi.org/10.1073/pnas.0601643103
  12. Lamoureux F, Picarda G, Garrigue-Antar L, Baud'huin M, Trichet V, Vidal A, Miot-Noirault E, Pitard B, Heymann D, Redini F. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res 2009;69:526-536 https://doi.org/10.1158/0008-5472.CAN-08-2648
  13. Lee EJ, Choi EM, Kim SR, Park JH, Kim H, Ha KS, Kim YM, Kim SS, Choe M, Kim JI, Han JA. Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells. Exp Mol Med 2007;39:469-476 https://doi.org/10.1038/emm.2007.51
  14. Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther 2007;6:3219-3228 https://doi.org/10.1158/1535-7163.MCT-07-0275
  15. Mahalingam D, Szegezdi E, Keane M, Jong S, Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 2009;35:280-288 https://doi.org/10.1016/j.ctrv.2008.11.006
  16. Mirandola P, Sponzilli I, Gobbi G, Marmiroli S, Rinaldi L, Binazzi R, Piccari GG, Ramazzotti G, Gaboardi GC, Cocco L, Vitale M. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins. Int J Oncol 2006;28:127-133
  17. Patterson MK Jr. Measurement of growth and viability of cells in culture. Methods Enzymol 1979;58:141-152
  18. Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, Broadley K. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004;8:1-176
  19. Roux C, Dougados M. Treatment of Patients with Pagets Disease of Bone. Drugs 1999;58:823-830 https://doi.org/10.2165/00003495-199958050-00005
  20. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-759 https://doi.org/10.1007/s00198-007-0540-8
  21. Seol JW, Chaudhari AA, Lee YJ, Kang HS, Kim IS, Kim NS, Park JH, Kim TH, Seol DW, Park SY. Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep 2007;18: 523-529
  22. Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, Kim K, Kim SJ, Hong SS, Park JH. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 2002;34:114-122 https://doi.org/10.1038/emm.2002.17

Cited by

  1. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T‐cell‐mediated cytotoxicity by zoledronate vol.30, pp.5, 2011, https://doi.org/10.1002/jor.21579
  2. Vitamin E Succinic Acid enhances the effect of mDRA-6 to eradicate leukemia cells by inducing apoptosis vol.11, pp.4, 2011, https://doi.org/10.1007/s10330-011-0922-4
  3. Oxaliplatin Sensitizes OS Cells to TRAIL-induced Apoptosis Via Down-regulation of Mcl1 vol.13, pp.7, 2011, https://doi.org/10.7314/apjcp.2012.13.7.3477
  4. Antiobesity activity of a sphingosine 1-phosphate analogue FTY720 observed in adipocytes and obese mouse model vol.44, pp.10, 2012, https://doi.org/10.3858/emm.2012.44.10.069
  5. Kurarinone promotes TRAIL-induced apoptosis by inhibiting NF-κB-dependent cFLIP expression in HeLa cells vol.44, pp.11, 2011, https://doi.org/10.3858/emm.2012.44.11.074
  6. A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells vol.62, pp.8, 2011, https://doi.org/10.1007/s00262-013-1439-1
  7. Sphingosine-1-phosphate inhibits the adipogenic differentiation of 3T3-L1 preadipocytes vol.34, pp.4, 2011, https://doi.org/10.3892/ijmm.2014.1856
  8. Claudin-7 suppresses the cytotoxicity of TRAIL-expressing mesenchymal stem cells in H460 human non-small cell lung cancer cells vol.19, pp.3, 2011, https://doi.org/10.1007/s10495-013-0938-z
  9. Mesenchymal Progenitors Expressing TRAIL Induce Apoptosis in Sarcomas vol.33, pp.3, 2011, https://doi.org/10.1002/stem.1903
  10. A novel adenoviral vector carrying an all-in-one Tet-On system with an autoregulatory loop for tight, inducible transgene expression vol.15, pp.None, 2011, https://doi.org/10.1186/s12896-015-0121-4
  11. Activation of S1P2 receptor, a possible mechanism of inhibition of adipogenic differentiation by sphingosine 1-phosphate vol.11, pp.2, 2015, https://doi.org/10.3892/mmr.2014.2810
  12. Modulation of the expression of sphingosine 1-phosphate 2 receptors regulates the differentiation of pre-adipocytes vol.12, pp.5, 2011, https://doi.org/10.3892/mmr.2015.4388
  13. Celastrol increases osteosarcoma cell lysis by γδ T cells through up-regulation of death receptors vol.7, pp.51, 2011, https://doi.org/10.18632/oncotarget.12756
  14. Combined application of Embelin and tumor necrosis factor-related apoptosis-inducing ligand inhibits proliferation and invasion in osteosarcoma cells via caspase-induced apoptosis vol.15, pp.5, 2011, https://doi.org/10.3892/ol.2018.8209
  15. In Vitro Studies on the Influence of Meloxicam on Cytotoxic Activity Induced by Risedronate Sodium in Canine (D-17) and Human (U-2 OS) Osteosarcoma Cell Lines vol.11, pp.11, 2011, https://doi.org/10.3390/ani11113135